The Clorox Company $CLX Stock Position Decreased by Algert Global LLC

Key Points

• Algert Global LLC has drastically cut its holdings in The Clorox Company by 87%, selling over 25,000 shares and reducing its ownership to 3,750 shares worth approximately $552,000.
• Clorox reported earnings per share (EPS) of $2.87 for the last quarter, exceeding analysts' expectations of $2.24, with revenues increasing by 4.5% year-over-year.
• The company announced an increase in its quarterly dividend to $1.24 per share, which reflects a yield of 4.1% and signals positive financial performance despite market pressures.

Algert Global LLC lessened its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 87.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,750 shares of the company's stock after selling 25,119 shares during the period. Algert Global LLC's holdings in Clorox were worth $552,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Sonora Investment Management Group LLC grew its position in shares of Clorox by 2.5% during the 1st quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock valued at $433,000 after buying an additional 72 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Clorox by 0.6% during the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company's stock valued at $1,953,000 after purchasing an additional 73 shares during the period. Horizon Investments LLC boosted its stake in Clorox by 4.4% during the 1st quarter. Horizon Investments LLC now owns 1,768 shares of the company's stock valued at $258,000 after purchasing an additional 75 shares during the period. Sfmg LLC boosted its stake in Clorox by 2.8% during the 1st quarter. Sfmg LLC now owns 2,780 shares of the company's stock valued at $409,000 after purchasing an additional 76 shares during the period. Finally, Financial Avengers Inc. boosted its stake in Clorox by 32.1% during the 4th quarter. Financial Avengers Inc. now owns 457 shares of the company's stock valued at $74,000 after purchasing an additional 111 shares during the period. Institutional investors own 78.53% of the company's stock.

Wall Street Analyst Weigh In

CLX has been the subject of a number of analyst reports. JPMorgan Chase & Co. reduced their target price on shares of Clorox from $144.00 to $140.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Jefferies Financial Group reduced their target price on shares of Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Barclays reduced their target price on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating for the company in a research note on Tuesday, July 15th. Wells Fargo & Company boosted their target price on shares of Clorox from $135.00 to $138.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Finally, Evercore ISI set a $140.00 target price on shares of Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Reduce" and an average price target of $143.36.

Clorox Stock Performance

Shares of NYSE CLX opened at $120.1760 on Friday. The stock has a fifty day moving average price of $124.25 and a two-hundred day moving average price of $135.30. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The firm has a market cap of $14.70 billion, a P/E ratio of 18.43, a PEG ratio of 0.96 and a beta of 0.49. The Clorox Company has a 1 year low of $117.35 and a 1 year high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.24 by $0.63. The firm had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the company posted $1.82 EPS. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Research analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 29th. Investors of record on Wednesday, August 13th will be issued a dividend of $1.24 per share. The ex-dividend date is Wednesday, August 13th. This is a positive change from Clorox's previous quarterly dividend of $1.22. This represents a $4.96 dividend on an annualized basis and a yield of 4.1%. Clorox's payout ratio is 76.07%.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.